Sionna Therapeutics (NASDAQ:SION) Director Sells $10,287,918.04 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 226,906 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $45.34, for a total transaction of $10,287,918.04. Following the transaction, the director directly owned 3,020,119 shares in the company, valued at $136,932,195.46. The trade was a 6.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14.
• On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54.
• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.57, for a total transaction of $84,237.30.

Sionna Therapeutics Stock Performance

Shares of SION opened at $43.54 on Friday. The company’s 50 day moving average price is $37.74 and its 200 day moving average price is $38.39. Sionna Therapeutics, Inc. has a 52 week low of $10.07 and a 52 week high of $46.46. The company has a market capitalization of $1.96 billion, a PE ratio of -22.33 and a beta of 3.01.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15.

Sionna Therapeutics News Roundup

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: The company reported an EPS beat on March 2 (reported -$0.46 vs. consensus -$0.61), a fundamental datapoint that supports investor sentiment and helps explain why the stock has traded above its 50/200‑day averages.
• Positive Sentiment: Despite selling, the reporting director (Orbimed / Peter A. Thompson) still holds a very large stake (roughly 3.0–3.5M shares), which tempers the interpretation that insiders are deserting the company.
• Neutral Sentiment: Many of the reported sales were executed under pre‑arranged Rule 10b5‑1 plans, which reduces the likelihood the trades reflect new negative private information.
• Neutral Sentiment: Analyst coverage is skewed positive: multiple buy/strong‑buy ratings and an average target (~$50.6) provide a supportive backdrop for sentiment.
• Negative Sentiment: Large, consecutive insider sell filings on April 14–16 total roughly 510K shares (~$22–23M at reported prices). That scale of director selling can create short‑term downward pressure and trigger investor concern despite 10b5‑1 protections. InsiderTrades Alert SEC Filing

Institutional Trading of Sionna Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its position in Sionna Therapeutics by 4.5% in the fourth quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock worth $413,000 after acquiring an additional 433 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Sionna Therapeutics by 8.8% in the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after buying an additional 529 shares during the last quarter. MetLife Investment Management LLC lifted its stake in shares of Sionna Therapeutics by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock worth $352,000 after buying an additional 532 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Sionna Therapeutics by 35.2% in the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Sionna Therapeutics in the fourth quarter worth $36,000.

Analysts Set New Price Targets

A number of research analysts recently commented on SION shares. Citizens Jmp started coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Citigroup assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating for the company. Lifesci Capital raised shares of Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Finally, BTIG Research reissued a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $50.57.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.